LTUS — Lotus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
- $10.24m
- $15.49m
- $72.70m
C2006 December 31st | 2007 December 31st | C2008 December 31st | C2009 December 31st | 2010 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Other Revenue | |||||
Total Revenue | 36.2 | 56.9 | 73.8 | 56.5 | 72.7 |
Cost of Revenue | |||||
Gross Profit | 2.83 | 11.4 | 27.5 | 31.4 | 39.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 31.7 | 43.4 | 58.7 | 38.5 | 58.2 |
Operating Profit | 4.47 | 13.5 | 15.1 | 18 | 14.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4.14 | 11.2 | 12.8 | 16.8 | 14.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4.14 | 11.2 | 12.8 | 16.4 | 14.4 |
Net Income Before Extraordinary Items | |||||
Net Income | 4.14 | 11.2 | 12.8 | 16.4 | 14.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 4.14 | 11.2 | 12.8 | 16.4 | 14.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.205 | 0.413 | 0.532 | 0.724 | 0.782 |
Dividends per Share |